Anti-CD38 monoclonal antibodies – a new drug class for treating myeloma

A New "Moda" Targeting CD38 in Multiple Myeloma with Noa Biran, MD, John TheurerПодробнее

Multiple Myeloma - 2023 Best of Hematology ConferenceПодробнее

March 15, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)Подробнее

Myeloma Made Simple: Drug Classes Made Simple | The Main Types of Drug Used to Treat MyelomaПодробнее

Sequencing BCMA Myeloma TherapiesПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Kenneth C. Anderson - Multiple myeloma cured in 2030: what are the next steps?Подробнее

Relapsed Refractory Multiple Myeloma | Current Treatment Options | Options on the HorizonПодробнее

The Future of Antibody Therapies and Drug Conjugates in Multiple MyelomaПодробнее

Relapsed multiple myeloma responds to combination therapy with daratumumabПодробнее

Melflufen for Myeloma: A Deep DiveПодробнее

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myelomaПодробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

Bench to Bedside Immune Therapies in Multiple Myeloma | Ken AndersonПодробнее

Clinical Trials in Multiple MyelomaПодробнее